• NF 449: From P2X1 Blockade to Assay Design

  2026-09-08

  NF 449 is a potent purinergic receptor antagonist for resolving P2X1-dependent platelet signaling. This guide interprets potency across recombinant, native-cell, and thrombosis models while translating the evidence into better platelet assay design.

• Fucoidan and Cancer Plasticity: A Translational Roadmap

  2026-09-08

  Fucoidan is more than a broadly described marine polysaccharide: its apoptosis, angiogenesis, and immune-modulating activities create a useful framework for translational oncology. This article connects those findings with cancer-cell plasticity research and outlines a disciplined path from mechanistic hypothesis to reproducible model validation.

• Triptolide (PG490) Experimental Workflow

  2026-09-07

  Triptolide (PG490) is a nanomolar transcriptional perturbagen for cancer, immune, and inflammatory research. This guide translates its RNAPII, IL-2, NF-κB, MMP, and AhR–HSF1 applications into practical workflows, controls, and troubleshooting strategies.

• CB-839 Workflow for Glutamine Metabolism

  2026-09-07

  CB-839 (Telaglenastat) provides a selective, reversible way to test whether GLS1-dependent glutaminolysis supports tumor-cell growth, metabolic fitness, or stress adaptation. This workflow connects dose-response pharmacology with metabolite, apoptosis, autophagy, and RNA-regulatory readouts for stronger preclinical cancer drug evaluation.

• Ajugol, Mitophagy, and Pyroptosis in Gouty Arthritis

  2026-09-05

  The reference study identifies impaired PINK1/Parkin-dependent mitophagy as a mechanistic link between PI3K/Akt/mTOR signaling and chondrocyte pyroptosis in acute gouty arthritis. Using computational analysis, human chondrocyte models, pharmacological perturbation, and MSU-induced mice, the authors show that ajugol protects cartilage by restoring mitochondrial quality control and limiting NLRP3 inflammasome activation.

• Recombinant Human Oncostatin M in Fibrosis Assays

  2026-09-04

  Recombinant Human Oncostatin M provides a defined cytokine perturbation for dissecting inflammatory and fibroproliferative circuits. This guide connects rh-Oncostatin M with mast cell–mesothelial crosstalk research while separating established findings from testable assay hypotheses.

• From NEXMIF Biology to qPCR Translation

  2026-09-04

  A translational framework for using targeted qPCR to validate NEXMIF dosage biology, connect transcriptomic findings with neuronal phenotypes, and build more reproducible gene expression workflows with HotStart™ Universal 2X Green qPCR Master Mix.

• Pam3CSK4 TFA for TLR1/2 Assays

  2026-09-03

  Pam3CSK4 TFA provides a defined, tunable trigger for separating TLR1/2-driven cytokine responses from the broader complexity of bacterial stimulation. This guide translates maternal–neonatal biomarker findings into practical assay design, stock handling, controls, optimization, and translational workflows.

• Bifendate (DDB): Translational Guardrails for Liver Research

  2026-09-03

  Bifendate (DDB) is best understood as a context-dependent hepatoprotection agent rather than a simple lipid-lowering compound. This thought-leadership guide connects its autophagy-related mechanisms, lipid phenotypes, formulation requirements, and CYP3A4-linked interaction risk to a more rigorous translational strategy.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis

  2026-09-02

  The reference study identifies a tumor-promoting communication route in which tumor-associated macrophage extracellular vesicles deliver miR-660 to breast cancer cells, suppressing KLHL21 and activating the IKKβ/NF-κB p65 axis. Its combination of tissue analysis, extracellular-vesicle co-culture, molecular perturbation, and mouse metastasis experiments provides a mechanistic framework for studying macrophage-driven dissemination.

• RNA G-Quadruplexes Shape TDP-43 Toxicity

  2026-09-02

  Oldani and colleagues show that RNA G-quadruplexes directly influence TDP-43 aggregation, intracellular distribution, and toxicity across biochemical, yeast, HEK293T, and motor-neuron-like cell models. The study supports structure-directed investigation of TDP-43 proteostasis while emphasizing that RNA G-quadruplex mechanisms should not be assumed to match DNA-focused stabilization strategies.

• ATS-9R/siCcl2 Targets ATMs in GDM

  2026-09-01

  The reference study developed an ATS-9R/siCcl2 oligopeptide complex to silence Ccl2 in adipose tissue macrophages and reduce inflammation-associated insulin resistance in gestational diabetes mellitus. Its main innovation is the combination of cell-directed non-viral RNA delivery with a mechanistic analysis linking Ccl2 suppression to reduced ER–mitochondrial calcium transfer and oxidative stress.

• Cucurbitacin I: Systems-Informed STAT3 Assays

  2026-09-01

  Cucurbitacin I, also known as JSI-124, is a selective pathway probe for linking STAT3 phosphorylation to transcriptional and cancer-cell phenotypes. This article applies assay-design principles from human SAN-plexus assembloids to build more rigorous, state-aware cancer experiments without conflating cardiac and oncology evidence.

• Why Acute Myeloid Leukemia Is Sensitive to Mitocans

  2026-08-31

  Panina et al. identify acute myeloid leukemia as unusually sensitive to mitochondrial-targeting drugs and connect this vulnerability to defects in mitochondrial metabolism and respiratory coupling. The study further shows that combining the mitochondrial uncoupler CCCP with the glycolytic inhibitor 2-deoxyglucose produces selective anti-leukemia effects, including in primary AML cells.

• Triptolide (PG490): Applied Research Workflows

  2026-08-31

  Build mechanism-led assays with Triptolide (PG490), from nanomolar ovarian cancer invasion studies to transcriptional and inflammatory pathway analysis. This guide connects practical DMSO handling, orthogonal readouts, and the latest AhR–RBX1–HSF1 findings to help researchers distinguish pathway-specific effects from general cytotoxicity.

8552 records 6/571 page Previous Next First page 上5页 678910 下5页 Last page